Literature DB >> 17934861

Gastrointestinal manifestations of systemic sclerosis.

Robyn Domsic1, Kenneth Fasanella, Klaus Bielefeldt.   

Abstract

Systemic sclerosis is a chronic disorder of connective tissue that affects the gastrointestinal tract in more than 80% of patients. Changes in neuromuscular function with progressive fibrosis of smooth muscle within the muscularis propria impair normal motor function, which may secondarily alter transit and nutrient absorption. Esophageal manifestations with gastroesophageal reflux and dysphagia are the most common visceral manifestation of the disease, often requiring more intense acid-suppressive medication. Gastric involvement may lead to gastroparesis, which can be found in up to 50% of patients. Severe small bowel disease can present as chronic intestinal pseudo-obstruction with distended loops of small intestine, bacterial overgrowth, impaired absorption and progressive development of nutritional deficiencies. While not studied as extensively, systemic sclerosis often also affects colorectal function resulting in constipation, diarrhea or fecal incontinence. Nutritional support and prokinetics have been used with some success to manage gastric and small or large bowel involvement in patients with systemic sclerosis. Despite advances in management, significant gastrointestinal manifestations of systemic sclerosis still carry a poor prognosis with a five-year mortality exceeding 50%.

Entities:  

Mesh:

Year:  2007        PMID: 17934861     DOI: 10.1007/s10620-007-0018-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  81 in total

1.  Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.

Authors:  A Attar; B Flourié; J C Rambaud; C Franchisseur; P Ruszniewski; Y Bouhnik
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

Review 2.  Is scleroderma an autoantibody mediated disease?

Authors:  Frank C Arnett
Journal:  Curr Opin Rheumatol       Date:  2006-11       Impact factor: 5.006

3.  Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications.

Authors:  B W Jaffin; P Chang; H Spiera
Journal:  J Clin Gastroenterol       Date:  1997-10       Impact factor: 3.062

4.  Esophageal involvement and pulmonary manifestations in systemic sclerosis.

Authors:  I Marie; S Dominique; H Levesque; P Ducrotté; P Denis; M F Hellot; H Courtois
Journal:  Arthritis Rheum       Date:  2001-08

Review 5.  Diabetic gastropathy and prokinetics.

Authors:  Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

6.  Interdigestive motor activity in patients with systemic sclerosis.

Authors:  W D Rees; R J Leigh; N D Christofides; S R Bloom; L A Turnberg
Journal:  Gastroenterology       Date:  1982-09       Impact factor: 22.682

7.  Intestinal involvement in progressive systemic sclerosis detected by increased unconjugated serum bile acids.

Authors:  F Stellaard; T Sauerbruch; C H Luderschmidt; B Leisner; G Paumgartner
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

8.  Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence.

Authors:  Gregory J Heyt; Mina K Oh; Nazanin Alemzadeh; Susie Rivera; Sergio A Jimenez; Satish Rattan; Sidney Cohen; Anthony J Dimarino
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

9.  A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma).

Authors:  C G P Roberts; L K Hummers; W J Ravich; F M Wigley; G M Hutchins
Journal:  Gut       Date:  2006-03-09       Impact factor: 23.059

10.  Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response.

Authors:  A V Emmanuel; A G Shand; M A Kamm
Journal:  Aliment Pharmacol Ther       Date:  2004-03-15       Impact factor: 8.171

View more
  23 in total

1.  Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.

Authors:  Nicolas Richard; Marie Hudson; Mianbo Wang; Geneviève Gyger; Susanna Proudman; Wendy Stevens; Mandana Nikpour; Murray Baron
Journal:  Rheumatology (Oxford)       Date:  2019-04-01       Impact factor: 7.580

2.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

Review 3.  Functional autoantibodies in systemic sclerosis pathogenesis.

Authors:  Angela Kill; Gabriela Riemekasten
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

Review 4.  Small intestinal bacterial overgrowth syndrome.

Authors:  Jan Bures; Jiri Cyrany; Darina Kohoutova; Miroslav Förstl; Stanislav Rejchrt; Jaroslav Kvetina; Viktor Vorisek; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

Review 5.  Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis.

Authors:  Xin Feng; Xiao-Qing Li; Zheng Jiang
Journal:  Clin Rheumatol       Date:  2021-01-11       Impact factor: 2.980

Review 6.  Intestinal Involvement in Systemic Sclerosis: A Clinical Review.

Authors:  Lazaros I Sakkas; Theodora Simopoulou; Dimitrios Daoussis; Stamatis-Nick Liossis; Spyros Potamianos
Journal:  Dig Dis Sci       Date:  2018-02-21       Impact factor: 3.199

7.  Different faces of gastroparesis.

Authors:  Klaus Bielefeldt; Naeem Raza; Susan L Zickmund
Journal:  World J Gastroenterol       Date:  2009-12-28       Impact factor: 5.742

8.  Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Med Res Arch       Date:  2020-10-29

9.  Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.

Authors:  Jagmohan Singh; Vaibhav Mehendiratta; Francesco Del Galdo; Sergio A Jimenez; Sidney Cohen; Anthony J DiMarino; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-09-24       Impact factor: 4.052

Review 10.  [Scleroderma and fibrosing diseases].

Authors:  U A Walker; P Knöss; M Jakobs; V Krenn
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.